PI3K inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “PI3K inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
PI3K inhibitors: Overview
Phosphatidylinositol-3 kinases (PI3Ks) are lipid kinases that phosphorylate signaling lipid PIP2 to PIP3. PIP3 molecules recruit proteins bearing PIP3-binding pleckstrin homology (PH) domains such as Akt in the PI3K/Akt/mTOR signaling pathway to the plasma membrane. The PI3K pathway is among the most frequently activated in human cancers, impacting almost 50% of the malignancies. Class IA isoforms PI3K?, ? and ? are particularly strongly associated with cancer.Activating mutations in the PIK3CA gene, which encodes the p110? catalytic subunit of PI3K? and suppressing mutations of tumor suppressor PTEN5,6 (a lipid phosphatase that dephosphorylates PIP3, thus opposes PI3K? action) are the second and third most frequently mutated in cancer, making PI3K? a vastly important target for drug discovery
PI3K inhibitors Emerging Drugs Chapters
This segment of the PI3K inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PI3K inhibitors Emerging Drugs
Further product details are provided in the report……..
PI3K inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PI3K inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
PI3K inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PI3K inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PI3K inhibitors drugs.
Report Highlights
DelveInsight’s, “PI3K inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
PI3K inhibitors: Overview
Phosphatidylinositol-3 kinases (PI3Ks) are lipid kinases that phosphorylate signaling lipid PIP2 to PIP3. PIP3 molecules recruit proteins bearing PIP3-binding pleckstrin homology (PH) domains such as Akt in the PI3K/Akt/mTOR signaling pathway to the plasma membrane. The PI3K pathway is among the most frequently activated in human cancers, impacting almost 50% of the malignancies. Class IA isoforms PI3K?, ? and ? are particularly strongly associated with cancer.Activating mutations in the PIK3CA gene, which encodes the p110? catalytic subunit of PI3K? and suppressing mutations of tumor suppressor PTEN5,6 (a lipid phosphatase that dephosphorylates PIP3, thus opposes PI3K? action) are the second and third most frequently mutated in cancer, making PI3K? a vastly important target for drug discovery
PI3K inhibitors Emerging Drugs Chapters
This segment of the PI3K inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PI3K inhibitors Emerging Drugs
- Umbralisib: TG Therapeutics
- Gedatolisib: Pfizer
- Parsaclisib: Incyte Corporation
- YH 25248: Yuhan
Further product details are provided in the report……..
PI3K inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PI3K inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in PI3K inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
PI3K inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PI3K inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PI3K inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence PI3K inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- In May 2019, Onconova to receive USD 4 Million upfront, including USD 2 Million Fee and USD 2 Million for Onconova Shares Purchased at a Premium, Plus up to USD 45.5 Million in Regulatory and Sales Milestones for Rigosertib in Greater China.
- In December 2019, Onconova Therapeutics, and Inceptua Medicines announced that they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.
- PI3K inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- What are the current treatment options available based on the PI3K inhibitors?
- How many companies are developing therapies by working on PI3K inhibitors?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for PI3K inhibitors to treat disease condition?
- How many emerging therapies are in early-stage, mid-stage, and late stage of development for PI3K inhibitors?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the PI3K inhibitors therapies?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies developed based on this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for PI3K inhibitors and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for PI3K inhibitors?
- How many patents are granted and pending for the emerging therapies of PI3K inhibitors?
- TG Therapeutics
- Pfizer
- Incyte Corporation
- Yuhan
- Inflection Biosciences/AUM Biosciences
- Onconova Therapeutics
- UCB
- Umbralisib
- Gedatolisib
- Parsaclisib
- YH 25248
- Research programme: anti-cancer therapeutics
- Rigosertib
- Seletalisib
Introduction
Executive Summary
PI3K inhibitors: Overview
• Classification
• Mechanism of Action
• Structure
• Application
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
PI3K inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• PI3K inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
PI3K inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Umbralisib: TG Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
Gedatolisib: Pfizer
• Product Description
• Research and Development
• Product Development Activities
Parsaclisib: Incyte Corporation
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
YH 25248: Yuhan
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
• Comparative Analysis
PI3K inhibitors Key Companies
PI3K inhibitors Key Products
PI3K inhibitors- Unmet Needs
PI3K inhibitors- Market Drivers and Barriers
PI3K inhibitors- Future Perspectives and Conclusion
PI3K inhibitors Analyst Views
PI3K inhibitors Key Companies
Appendix
Executive Summary
PI3K inhibitors: Overview
• Classification
• Mechanism of Action
• Structure
• Application
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
PI3K inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• PI3K inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
PI3K inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Umbralisib: TG Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
Gedatolisib: Pfizer
• Product Description
• Research and Development
• Product Development Activities
Parsaclisib: Incyte Corporation
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
YH 25248: Yuhan
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
• Comparative Analysis
PI3K inhibitors Key Companies
PI3K inhibitors Key Products
PI3K inhibitors- Unmet Needs
PI3K inhibitors- Market Drivers and Barriers
PI3K inhibitors- Future Perspectives and Conclusion
PI3K inhibitors Analyst Views
PI3K inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for PI3K inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for PI3K inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for PI3K inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for PI3K inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
